{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:02:21Z","timestamp":1783472541462,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40266-025-01271-9","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:34:06Z","timestamp":1767162846000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Implants to Treat Glaucoma: Promising or Not?"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7402-1854","authenticated-orcid":false,"given":"Barbara","family":"Cvenkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"1","key":"1271_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/bjophthalmol-2015-307223","volume":"100","author":"VV Kapetanakis","year":"2016","unstructured":"Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86\u201393.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1271_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"issue":"10414","key":"1271_CR3","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet. 2023;402(10414):1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(23)01289-8.","journal-title":"Lancet"},{"issue":"10","key":"1271_CR4","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s00417-023-06050-z","volume":"261","author":"K Latif","year":"2023","unstructured":"Latif K, Nishida T, Moghimi S, Weinreb RN. Quality of life in glaucoma. Graefes Arch Clin Exp Ophthalmol. 2023;261(10):3023\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1271_CR5","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.4.2.1","volume":"4","author":"R Susanna Jr.","year":"2015","unstructured":"Susanna R Jr., De Moraes CG, Cioffi GA, Ritch R. Why do people (still) go blind from glaucoma? Transl Vis Sci Technol. 2015;4(2):1. https:\/\/doi.org\/10.1167\/tvst.4.2.1.","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"1271_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2007.09.013","volume":"145","author":"F Topouzis","year":"2008","unstructured":"Topouzis F, Coleman AL, Harris A, Koskosas A, Founti P, Gong G, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol. 2008;145(2):327\u201335.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1271_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"1271_CR8","doi-asserted-by":"crossref","unstructured":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429\u201340.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"issue":"9975","key":"1271_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295\u2013304.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1271_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","volume":"109","author":"M Pazos","year":"2025","unstructured":"Pazos M, Traverso CE, Viswanathan A. European Glaucoma Society\u2014terminology and guidelines for glaucoma, 6th edition. Br J Ophthalmol. 2025;109(Suppl 1):1\u2013212.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"1271_CR11","first-page":"1","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma, 5th edition. Br J Ophthalmol. 2021;105(Suppl 1):1\u2013169.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1271_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129\u201340.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"1271_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2023-egsguidelines","volume":"107","author":"L Abegao Pinto","year":"2023","unstructured":"Abegao Pinto L, Sunaric Megevand G, Stalmans I, Azuara-Blanco A, Bron A, Garcia Feijoo J, et al. European Glaucoma Society\u2014a guide on surgical innovation for glaucoma. Br J Ophthalmol. 2023;107(Suppl 1):1\u2013114.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1271_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/ceo.14028","volume":"50","author":"R Lim","year":"2022","unstructured":"Lim R. The surgical management of glaucoma: a review. Clin Experiment Ophthalmol. 2022;50(2):213\u201331.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"5","key":"1271_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/ICU.0000000000001077","volume":"35","author":"A Sharma","year":"2024","unstructured":"Sharma A, Tijerina JD, Bitrian E. Minimally invasive, maximally impactful: minimally invasive glaucoma surgery and the changing glaucoma landscape. Curr Opin Ophthalmol. 2024;35(5):409\u201314.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"1271_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ceo.13989","volume":"50","author":"RJ Casson","year":"2022","unstructured":"Casson RJ. Medical therapy for glaucoma: a review. Clin Exp Ophthalmol. 2022;50(2):198\u2013212.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4-5","key":"1271_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","volume":"14","author":"AL Robin","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019;14(4\u20135):199\u2013210.","journal-title":"Expert Rev Ophthalmol"},{"issue":"12","key":"1271_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","volume":"132","author":"DK Hwang","year":"2014","unstructured":"Hwang DK, Liu CJ, Pu CY, Chou YJ, Chou P. Persistence of topical glaucoma medication: a nationwide population-based cohort study in Taiwan. JAMA Ophthalmol. 2014;132(12):1446\u201352.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1271_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308\u201316.","journal-title":"Ophthalmology"},{"key":"1271_CR20","doi-asserted-by":"publisher","unstructured":"Kolko M, Faergemann Hansen R, L GD, Sabelstrom E, Brandel M, Hoiberg Bentsen A, et al. Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark-an observational registry study of 30 100 Danish patients with glaucoma. BMJ Open Ophthalmol. 2024;9(1). https:\/\/doi.org\/10.1136\/bmjophth-2023-001607.","DOI":"10.1136\/bmjophth-2023-001607"},{"issue":"4","key":"1271_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/eye.2008.103","volume":"23","author":"J Lacey","year":"2009","unstructured":"Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye. 2009;23(4):924\u201332.","journal-title":"Eye"},{"issue":"7","key":"1271_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","volume":"115","author":"J Caprioli","year":"2008","unstructured":"Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123\u20139.","journal-title":"Ophthalmology"},{"issue":"5","key":"1271_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archophthalmol.2011.72","volume":"129","author":"CG De Moraes","year":"2011","unstructured":"De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol. 2011;129(5):562\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"1271_CR24","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398\u2013402.","journal-title":"Ophthalmology"},{"issue":"4","key":"1271_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2020;127(4):477\u201383.","journal-title":"Ophthalmology"},{"issue":"3","key":"1271_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/08820538.2021.1963788","volume":"37","author":"KL Buehne","year":"2022","unstructured":"Buehne KL, Rosdahl JA, Muir KW. Aiding adherence to glaucoma medications: a systematic review. Semin Ophthalmol. 2022;37(3):313\u201323.","journal-title":"Semin Ophthalmol"},{"key":"1271_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010151","author":"B Cvenkel","year":"2022","unstructured":"Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: a narrative review. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm12010151.","journal-title":"J Clin Med"},{"issue":"6","key":"1271_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","volume":"37","author":"M Shirley","year":"2020","unstructured":"Shirley M. Bimatoprost implant: first approval. Drugs Aging. 2020;37(6):457\u201362.","journal-title":"Drugs Aging"},{"issue":"3","key":"1271_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/08820538.2021.1985145","volume":"37","author":"PE Sirinek","year":"2022","unstructured":"Sirinek PE, Lin MM. Intracameral sustained release bimatoprost implants (Durysta). Semin Ophthalmol. 2022;37(3):385\u201390.","journal-title":"Semin Ophthalmol"},{"issue":"12","key":"1271_CR30","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","volume":"127","author":"FA Medeiros","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627\u201341.","journal-title":"Ophthalmology"},{"key":"1271_CR31","unstructured":"European Medicines Agency. Withdrawal of application for the marketing authorisation of Durysta (bimatoprost intracameral implant) 2024 [cited 2025 6 October]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_en.pdf."},{"key":"1271_CR32","unstructured":"European Medicines Agency. Withdrawal assessment report Durysta. 2024 [cited 2025 6 October]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/durysta."},{"issue":"5","key":"1271_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ophtha.2007.07.002","volume":"115","author":"KS Lim","year":"2008","unstructured":"Lim KS, Nau CB, O\u2019Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(5):790-5.e4.","journal-title":"Ophthalmology"},{"issue":"17","key":"1271_CR34","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, Belalcazar S, Thieme H, Goodkin ML, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017\u201333.","journal-title":"Drugs"},{"issue":"2","key":"1271_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40265-019-01248-0","volume":"80","author":"ER Craven","year":"2020","unstructured":"Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, et al. 24-month phase I\/II clinical trial of bimatoprost sustained-release implant (bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167\u201379.","journal-title":"Drugs"},{"issue":"3","key":"1271_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.64.3.15","volume":"64","author":"WD Stamer","year":"2023","unstructured":"Stamer WD, Perkumas KM, Kang MH, Dibas M, Robinson MR, Rhee DJ. Proposed mechanism of long-term intraocular pressure lowering with the bimatoprost implant. Invest Ophthalmol Vis Sci. 2023;64(3):15. https:\/\/doi.org\/10.1167\/iovs.64.3.15.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1271_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/DDDT.S506520","volume":"19","author":"I Vagiakis","year":"2025","unstructured":"Vagiakis I, Papadopoulou EP, Amaxilati E, Tsiropoulos GN, Konstas AG, Panos GD. Bimatoprost intracameral implant (Durysta(R)): a new era in glaucoma management through sustained-release innovation. Drug Des Devel Ther. 2025;19:703\u201314.","journal-title":"Drug Des Devel Ther"},{"key":"1271_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/OPTH.S445005","volume":"18","author":"S Teymoorian","year":"2024","unstructured":"Teymoorian S, Craven ER, Nguyen L, Werts E. Real-world study of the effectiveness and safety of intracameral bimatoprost implant in a clinical setting in the United States. Clin Ophthalmol. 2024;18:187\u201399.","journal-title":"Clin Ophthalmol"},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S452159","volume":"18","author":"SR Sarkisian Jr","year":"2024","unstructured":"Sarkisian SR Jr, Mitchell EC. Real-world analysis of the efficacy of bimatoprost sustained-release glaucoma implant where American Indians Comprise the Largest Minority Population. Clin Ophthalmol. 2024;18:917\u201327.","journal-title":"Clin Ophthalmol"},{"key":"1271_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/OPTH.S450220","volume":"18","author":"AA Ali","year":"2024","unstructured":"Ali AA, Aviles Elescano D, Grover DS. Bimatoprost SR for glaucoma therapy implanted at the slit-lamp in a real-world setting. Clin Ophthalmol. 2024;18:1371\u20137.","journal-title":"Clin Ophthalmol"},{"key":"1271_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ajo.2024.12.026","volume":"272","author":"M Kolko","year":"2025","unstructured":"Kolko M, Tatham AJ, Lim KS, Wells AP, Shiu M, Uy HS, et al. Phase 3, randomized, comparison study of intracameral bimatoprost implant 10 microg and selective laser trabeculoplasty. Am J Ophthalmol. 2025;272:19\u201337.","journal-title":"Am J Ophthalmol"},{"key":"1271_CR42","unstructured":"Stewart J. IDose TR FDA approval history. 2024 [cited 2025 10 October]. Available from: https:\/\/www.drugs.com\/history\/idose-tr.html."},{"issue":"1","key":"1271_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","volume":"84","author":"JP Berdahl","year":"2024","unstructured":"Berdahl JP, Sarkisian SR Jr, Ang RE, Doan LV, Kothe AC, Usner DW, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. 2024;84(1):83\u201397.","journal-title":"Drugs"},{"key":"1271_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/OPTH.S498431","volume":"19","author":"S Teymoorian","year":"2025","unstructured":"Teymoorian S, Kaur J. Travoprost intracameral implant in eyes with glaucoma or ocular hypertension: early short-term real-world outcomes. Clin Ophthalmol. 2025;19:157\u201366.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1271_CR45","first-page":"11","volume":"1","author":"P Denis","year":"2007","unstructured":"Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007;1(1):11\u201324.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1271_CR46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40123-024-00898-y","volume":"13","author":"SR Sarkisian","year":"2024","unstructured":"Sarkisian SR, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, et al. Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial. Ophthalmol Ther. 2024;13(4):995\u20131014.","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"1271_CR47","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40265-024-02074-9","volume":"84","author":"IP Singh","year":"2024","unstructured":"Singh IP, Berdahl JP, Sarkisian SR Jr, Voskanyan LA, Ang RE, Doan LV, et al. Long-term safety and efficacy evaluation of travoprost intracameral implant based on pooled analyses from two phase III trials. Drugs. 2024;84(10):1299\u2013311.","journal-title":"Drugs"},{"issue":"9","key":"1271_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ophtha.2024.02.022","volume":"131","author":"SR Sarkisian Jr","year":"2024","unstructured":"Sarkisian SR Jr, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, et al. Phase 3 randomized clinical trial of the safety and efficacy of travoprost intraocular implant in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2024;131(9):1021\u201332.","journal-title":"Ophthalmology"},{"issue":"9","key":"1271_CR49","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s40123-024-00992-1","volume":"13","author":"J Bacharach","year":"2024","unstructured":"Bacharach J, Doan LV, Stephens KG, Usner DW, Kothe AC, Katz LJ, et al. Travoprost intracameral implant demonstrates superior IOP lowering versus topical prostaglandin analog monotherapy in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2024;13(9):2357\u201367.","journal-title":"Ophthalmol Ther"},{"key":"1271_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/25158414241310275","author":"IP Singh","year":"2025","unstructured":"Singh IP, Voskanyan LA, Barber KM, Burden JH, Connolly L, Katz LJ, et al. Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery. Ther Adv Ophthalmol. 2025. https:\/\/doi.org\/10.1177\/25158414241310275.","journal-title":"Ther Adv Ophthalmol"},{"key":"1271_CR51","unstructured":"Envisia therapeutics. envisia therapeutics announces positive three-month interim results of low dose ENV515 in patients with glaucoma. 2016 [cited 2025 16 July]. Available from: https:\/\/www.prnewswire.com\/news-releases\/envisia-therapeutics-announces-positive-three-month-interim-results-of-low-dose-env515-in-patients-with-glaucoma-300261688.html."},{"key":"1271_CR52","unstructured":"Ocular Therapeutix. Ocular Therapeutix\u2122 announces positive phase 2 PAXTRAVA\u2122 glaucoma data at the American Society of Cataract and Refractive Surgery 2024 annual meeting. 2024 [cited 2025 16 July]. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/04\/06\/2858799\/0\/en\/Ocular-Therapeutix-Announces-Positive-Phase-2-PAXTRAVA-Glaucoma-Data-at-the-American-Society-of-Cataract-and-Refractive-Surgery-2024-Annual-Meeting.html."},{"key":"1271_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100901","volume":"82","author":"UB Kompella","year":"2021","unstructured":"Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2021;82:100901. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100901.","journal-title":"Prog Retin Eye Res"},{"issue":"14","key":"1271_CR54","first-page":"5095","volume":"53","author":"DF Goldberg","year":"2012","unstructured":"Goldberg DF, Williams R. A phase 2 study evaluating safety and efficacy of the latanoprost punctal plug delivery system (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). Invest Ophthalmol Vis Sci. 2012;53(14):5095.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1271_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/OPTH.S102181","volume":"10","author":"SA Perera","year":"2016","unstructured":"Perera SA, Ting DS, Nongpiur ME, Chew PT, Aquino MC, Sng CC, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016;10:757\u201364.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1271_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","volume":"14","author":"NP Kesav","year":"2021","unstructured":"Kesav NP, Young CEC, Ertel MK, Seibold LK, Kahook MY. Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol. 2021;14(1):148\u201359.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"1271_CR57","first-page":"43","volume":"14","author":"P Lee","year":"1975","unstructured":"Lee P, Shen Y, Eberle M. The long-acting ocusert-pilocarpine system in the management of glaucoma. Invest Ophthalmol. 1975;14(1):43\u20136.","journal-title":"Invest Ophthalmol"},{"issue":"8","key":"1271_CR58","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","volume":"123","author":"JD Brandt","year":"2016","unstructured":"Brandt JD, Sall K, DuBiner H, Benza R, Alster Y, Walker G, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123(8):1685\u201394.","journal-title":"Ophthalmology"},{"issue":"10","key":"1271_CR59","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.ophtha.2017.04.022","volume":"124","author":"JD Brandt","year":"2017","unstructured":"Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017;124(10):1565\u20136.","journal-title":"Ophthalmology"},{"issue":"14","key":"1271_CR60","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1021\/ie000596z","volume":"40","author":"JL Creech","year":"2001","unstructured":"Creech JL, Chauhan A, Radke CJ. Dispersive mixing in the posterior tear film under a soft contact lens. Ind Eng Chem Res. 2001;40(14):3015\u201326.","journal-title":"Ind Eng Chem Res"},{"key":"1271_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091163","author":"AM Fea","year":"2024","unstructured":"Fea AM, Vallino V, Cossu M, Marica V, Novarese C, Reibaldi M, et al. Drug delivery systems for glaucoma: a narrative review. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17091163.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1271_CR62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4155\/tde.10.40","volume":"1","author":"UB Kompella","year":"2010","unstructured":"Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1(3):435\u201356.","journal-title":"Ther Deliv"},{"key":"1271_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/polym13071102","author":"P Franco","year":"2021","unstructured":"Franco P, De Marco I. Contact lenses as ophthalmic drug delivery systems: a review. Polymers (Basel). 2021. https:\/\/doi.org\/10.3390\/polym13071102.","journal-title":"Polymers (Basel)"},{"key":"1271_CR64","unstructured":"American Academy of Ophthalmology. Subconjunctival latanoprost implant shows sustained IOP reduction through 3 months. Glaucoma Education Center 2017 [cited 2025 16 July]. Available from: https:\/\/www.aao.org\/education\/headline\/subconjunctival-latanaprost-implant-shows-sustaine."},{"issue":"4","key":"1271_CR65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13346-014-0196-9","volume":"4","author":"TT Wong","year":"2014","unstructured":"Wong TT, Novack GD, Natarajan JV, Ho CL, Htoon HM, Venkatraman SS. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2014;4(4):303\u20139.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"1271_CR66","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s40123-024-00965-4","volume":"13","author":"AM Elhusseiny","year":"2024","unstructured":"Elhusseiny AM, Aref AA. Sustained release therapies with the prostaglandin analogues intracameral implants. Ophthalmol Ther. 2024;13(7):1833\u20139.","journal-title":"Ophthalmol Ther"},{"key":"1271_CR67","unstructured":"Jarem L. A drug-eluting IOL may help expand glaucoma treatment options. 2025 [cited 2025 20 July]. Available from: https:\/\/www.aao.org\/education\/headline\/drug-eluting-iol-may-help-expand-glaucoma-treatmen."},{"issue":"1","key":"1271_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ogla.2021.04.011","volume":"5","author":"BC Stagg","year":"2022","unstructured":"Stagg BC, Granger A, Guetterman TC, Hess R, Lee PP. The burden of caring for and treating glaucoma: the patient perspective. Ophthalmol Glaucoma. 2022;5(1):32\u20139.","journal-title":"Ophthalmol Glaucoma"},{"issue":"16","key":"1271_CR69","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/s41433-023-02532-w","volume":"37","author":"A Safitri","year":"2023","unstructured":"Safitri A, Konstantakopoulou E, Hu K, Gazzard G. Treatment expectations in glaucoma: what matters most to patients? Eye. 2023;37(16):3446\u201354.","journal-title":"Eye"},{"issue":"2","key":"1271_CR70","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00417-023-06248-1","volume":"262","author":"C Weber","year":"2024","unstructured":"Weber C, Quintin P, Holz FG, Fea A, Mercieca K. Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic. Graefes Arch Clin Exp Ophthalmol. 2024;262(2):545\u201356.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1271_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","volume":"175","author":"RA Lewis","year":"2017","unstructured":"Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial. Am J Ophthalmol. 2017;175:137\u201347.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1271_CR72","first-page":"1913","volume":"65","author":"G Szekely","year":"2024","unstructured":"Szekely G, Katz LJ, Voskanyan LA, Chu I, Seal J, Yang J-Y, et al. Travoprost intraocular implant (iDose\u00ae TR) delivers therapeutically relevant and durable aqueous humor drug concentrations at 24 months and demonstrates safety of repeat implant administration. Invest Ophthalmol Vis Sci. 2024;65(7):1913.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1271_CR73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/jop.2022.0137","volume":"39","author":"RN Weinreb","year":"2023","unstructured":"Weinreb RN, Bacharach J, Brubaker JW, Medeiros FA, Bejanian M, Bernstein P, et al. Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies. J Ocul Pharmacol Ther. 2023;39(1):55\u201362.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1271_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cytogfr.2025.06.005","volume":"84","author":"A Nystuen","year":"2025","unstructured":"Nystuen A, Gonzalez-Lopez E, Kauper KA, Eade K, Aaberg TM Jr. Neuroprotective properties of ciliary neurotrophic factor in the retina for the treatment of macular telangiectasia type 2. Cytokine Growth Factor Rev. 2025;84:12\u20139. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.06.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"1271_CR75","first-page":"3292","volume":"43","author":"W Tao","year":"2002","unstructured":"Tao W, Wen R, Goddard MB, Sherman SD, O\u2019Rourke PJ, Stabila PF, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43(10):3292\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1271_CR76","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","volume":"126","author":"EY Chew","year":"2019","unstructured":"Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, et al. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. Ophthalmology. 2019;126(4):540\u20139.","journal-title":"Ophthalmology"},{"issue":"10","key":"1271_CR77","first-page":"3292","volume":"43","author":"W Tao","year":"2002","unstructured":"Tao W, Wen R, Goddard MB, Sherman SD, O\u2019Rourke PJ, Stabila PF, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43(10):3292\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1271_CR78","unstructured":"FDA. Center for Biologics Evaluation and Research (CBER) product approval information: ENCELTO. 2025 [cited 2025 18 July]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/center-biologics-evaluation-and-research-cber-product-approval-information\/encelto."},{"issue":"3","key":"1271_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100298","volume":"3","author":"JL Goldberg","year":"2023","unstructured":"Goldberg JL, Beykin G, Satterfield KR, Nunez M, Lam BL, Albini TA. Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement. Ophthalmol Sci. 2023;3(3):100298. https:\/\/doi.org\/10.1016\/j.xops.2023.100298.","journal-title":"Ophthalmol Sci"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01271-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:02:36Z","timestamp":1772125356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01271-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Barbara Cvenkel has received fees unrelated to the present publication for serving on an advisory board from Th\u00e9a Laboratories and lecturing fees from Th\u00e9a Laboratories and Santen. Miriam Kolko has received fees unrelated to the present publication as a speaker for AbbVie, Santen, Th\u00e9a Laboratories, and Topcon; and sits on advisory boards for AbbVie, Santen, and Th\u00e9a Laboratories.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"B.C. and M.K. drafted the first version of the manuscript; B.C. and M.K. contributed to the study concept and design and supervised the writing. Both authors discussed and commented on the manuscript and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}